Posted by on Nov 28, 2018 in Multiple Myeloma | 0 comments

In a nutshell This article investigated the safety and effectiveness of adding daratumumab (Darzalex) to bortezomib (Velcade) and dexamethasone (Decadron) for the treatment of relapsed or refractory (does not respond to treatment) multiple myeloma (RRMM). The authors concluded that the addition of daratumumab is safe and gave the greatest benefit to...

Read More